2021 Keynotes
Keynotes | Program 1-Feasibility | Program 2-Engagement | Program 3-Monitoring |
Program 4-Digitalization
Download Brochure
TUESDAY, 5 OCTOBER
11:45 Chairperson's Remarks
Nick Carroll, PhD, Transformation Lead, Digital Health, R&D, AstraZeneca
11:50 FIRESIDE CHAT: Combining Innovation and Collaboration to Advance Research Across the Industry...We Can’t Do it Alone
Sam Hariry, Global Head, Clinical Innovation, Novartis Institutes for BioMedical Research (NIBR)
Lewis Millen, Operations Innovation Lead, Global Clinical Sciences & Dev Solutions, UCB Pharma
The biopharma, medical device, digital medicine, healthcare and tech industries involved in clinical
research are learning from one another, improving innovation, re-thinking business process, and expanding what used to be a much more siloed ecosystem. These are exciting times, but it is a very complex garden to navigate. How do we continue to innovate
beyond pilots? How do we scale innovation and collaborate across departments, companies and industries to improve clinical trials and research?
12:20 Digital Transformation of an Entire Biopharma Company Look Like?
Francesca Wuttke, PhD, Chief Digital Officer, Almirall
Biopharma companies are trying to change business processes, drug discovery, manufacturing, clinical trials…their entire cultures,
to provide more digital solutions and services to their customers but it’s a long road. What are the main impediments to adoption? How can companies do different things (digitally enabled business models) rather than just do things differently
(digitization)? Where can companies find the best chance of success and how do they start? How can large pharma, biotech, specialty pharma and traditional life sci organizations transition?
12:30 Digital Health in the Circular Economy, Novel Partnerships Required
Bert Hartog, PhD, Senior Director Clinical Innovation, Janssen Pharmaceutica NV
The talk will be about the environmental impact of digital health, and how circular economy principles can help
minimize eWaste and maximize repurposing, reuse and recycling of digital health technologies.
12:40 PANEL DISCUSSION: What Can Clinical Innovation Teams Learn from Digital Health Startups?
PANEL MODERATOR:
Francesca Wuttke, PhD, Chief Digital Officer, Almirall SA
Working with startups can provide the Pharma industry with the innovation capabilities required to accelerate the digital transformation of the company, while embedding a culture of experimentation where there is freedom to try and fail, through
the exposure to and collaboration with young and risk-taking startups. Partnering with Startups offers Pharma access to solution-driven technology which allows them to accelerate their growth and drive strategy.
PANELISTS:
Andrea Coravos, CEO & Co-Founder, Elektra Labs
Bert Hartog, PhD, Senior Director Clinical Innovation, Janssen Pharmaceutica NV
Nader Alaghband, Co-Founder & CEO, Ampersand Health
WEDNESDAY, 6 OCTOBER
10:35 PANEL DISCUSSION: Special Catalan Ecosystem Panel: Digital Transformation and Clinical trials: The Next Challenge in Health
PANEL MODERATOR:
Montse Daban, Directcor, Scientific and International Relations, Biocat
The healthcare
community agrees on the need to foster digital transformation throughout the entire healthcare value chain, including the framework for the clinical validation of innovative technologies, i.e., the evidence for real-world positive and significant
health outcomes for patients and society. The final objective is to accelerate technology adoption, provide support for the validated ideas, and improve their market access. The session will share perspectives of actors connecting clinical research
and industry in a comprehensive way and it will highlight the successful coordination in clinical trials key stakeholders in Catalonia.
PANELISTS:
Montserrat Barcelo Riera, Vice President, Europe, Veristat
Xavier Cañas, Director, Promotion and Development of Clinical Research, Vall d’Hebron Hospital
Dani Prieto-Alhambra, MD, PhD, Professor, Pharmaco- and Device Epidemiology, University of Oxford
Lidia Cánovas, General Manager, Regulatory Affairs, Asphalion
11:05 Exhibit Hall Viewing
11:50 Chairperson's Remarks
Karl-Ludwig Radek, Internal Project Lead for IMI Trials@Home, Janssen
11:55 Harnessing the Power of Rea-World Data for Clinical Research: European Initiatives
Dipak Kalra, PhD, President, European Institute for Health Records and European Institute for Innovation through Health Data
Real World Data has historically been regarded as siloed within
healthcare provider systems (and therefore fragmented, difficult to access at scale), with patchy coverage and often of poor quality - so not very reliable for research. A further barrier is data protection legislation, in Europe with the GDPR. Large-scale
research infrastructure initiatives are now being established across Europe to tackle these issues and to make RWD more available for observational data studies and the reuse of EHRs for clinical trials. This talk will present this exciting landscape,
including the Commission proposals for a European Health Data Space, and explain how some of the perceived issues with RWD are being tackled, including winning public support for the use of RWD by industry.
12:15 PANEL DISCUSSION: Hybrid and Decentralized Trials: The Future is Here
PANEL MODERATOR:
Karl-Ludwig Radek, Internal Project Lead for IMI Trials@Home, Janssen
Covid-19 has played an extreme catalyst role in implementing existing digital and remote clinical trial solutions and
has been the engine behind rapid evolution of a few new capabilities. Some of these newly deployed capabilities are quick fixes for the emergency that COVID brought to our day-to-day trial operations, while many will benefit from the catalyst effect
and will probably be the new standard even after COVID. Today, we have the chance to continue driving adoption of decentralized clinical trials – and innovating to advance the benefits DCTs offer to patients, sites and sponsors.
PANELISTS:
Dipak Kalra, PhD, President, European Institute for Health Records & President, European Institute for Innovation through Health Data
Cristina De Juan, PhD, Innovation Lead, Global Clinical Sciences and Operations (GCSO), UCB
Joseph Kim, Head of Healthcare and Visual Analytics, Data Science & AI, AstraZeneca Biopharmaceuticals R&D
Marta Arias-Salgado Ruiz-Gimenez, Head of Quality & Continuous Improvement, Global Clinical Trials Organization, MSD
Kavita Rattan, PhD, Lead, AI-Data Sciences & RBM, Data Monitoring & Management, Pfizer Inc.